Details of the Drug
General Information of Drug (ID: DMDW8VX)
Drug Name |
N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide; CHEMBL191039; 77746-90-8; N-(2,5-diphenylpyrazol-3-yl)benzamide; AC1N4KII; Oprea1_790904; SCHEMBL2482825; CTK2G6100; DTXSID00400046; MolPort-003-805-392; HMS3519K01; ZINC3185886; BDBM50156065; AKOS005002190; MCULE-3316862201; DA-03411; FT-0732104; N-(1,3-Diphenyl-1H-pyrazole-5-yl)benzamide; N-(2,5-Diphenyl-2H-pyrazol-3-yl)-benzamide; Benzamide, N-(1,3-diphenyl-1H-pyrazol-5-yl)-
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure |
![]() |
|||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 339.4 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 4.7 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 4 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 2 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References